Craig Dubois, MD
Neurology · Mooresville, NCNPI 1164414819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,004 of the $68,503 with a category attached, or 65.7%. 60 manufacturers reported payments, led by Pfizer at 24.2% of the total. 2025 is the largest year on record at $20,955, 2.8 times the $7,430 reported in 2019. Among neurology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,315 payments — averaging $52.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$17K
- Teva Pharmaceuticals USA, Inc.$13K
- Biohaven Pharmaceuticals, Inc.$12K
- Biohaven Pharmaceutical Holding Company Ltd.$9K
- AbbVie$3K
- UCB, Inc.$1K
- plus $13K from 54 others
Across 7 payments — averaging $7441.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
- Bristol Myers Squibb$24K
- Teva Pharmaceuticals USA, Inc.$4K
What the payments were for
- Consulting fees$1,9003%
- Speaking & faculty fees$45,00466%
- Travel & lodging$2060%
- Food & beverage$21,35131%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$36,307
- AJOVY$11,020
- MYOBLOC$315
- BRIUMVI$135
- UBRELVY$122
- Xadago$122
- APOKYN$122
- XCOPRI$122
- Inspire$111
- INTELLIS ADAPTIVESTIM$102
How this compares
$68,503 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 81 | $713,643 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 43 | $536,059 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 31 | $493,901 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 37 | $452,476 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $383,167 |
| Kesimpta PenOfatumumab | 26 | $244,881 |
| AustedoDeutetrabenazine | 12 | $193,854 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $180,555 |
| BotoxOnabotulinumtoxina | 82 | $135,095 |
| NuplazidPimavanserin Tartrate | 24 | $132,142 |
| BriviactBrivaracetam | 81 | $123,697 |
| TysabriNatalizumab | 13 | $107,707 |
| Nurtec OdtRimegepant Sulfate | 49 | $66,635 |
| XcopriCenobamate | 37 | $48,652 |
| UbrelvyUbrogepant | 37 | $39,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga, Nurtec Odt, Eliquis | $16,569 | $774,898154 claims |
| Grifols USA, LLCGamunex-C | $63 | $713,64381 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $303 | $536,05943 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $13,095 | $193,85412 claims |
| AbbVieBotox, Ubrelvy | $2,990 | $174,548119 claims |
| Acadia Pharmaceuticals IncNuplazid | $622 | $132,14224 claims |
| UCB, Inc.Briviact | $1,038 | $123,69781 claims |
| BiogenTysabri | $542 | $107,70713 claims |
| SK Life Science, Inc.Xcopri | $858 | $48,65237 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $814 | $31,42212 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $279 | $15,13272 claims |
| MerckBelsomra | $71 | $10,64824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 566 neurology providers in North Carolina.
Other neurology in Mooresville
- Douglas JefferyMooresville$486K
- Andrew BraunsteinMooresville$222K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
- Kevin KahnDurham$587K
- Sanjay IyerCharlotte$581K
- Mark SkeenDurham$562K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.